Diffuse Large B Cell Lymphoma
269
57
89
69
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
21 trials with published results (8%)
Research Maturity
69 completed trials (26% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.4%
20 terminated out of 269 trials
77.5%
-9.0% vs benchmark
7%
19 trials in Phase 3/4
30%
21 of 69 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 69 completed trials
Clinical Trials (269)
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Thrombosis in Diffuse Large B-cell Lymphoma:the PREDIC-TO (PREDICt ThrOmbosis) Study
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution